The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
As an iron‐dependent lipid peroxidation (LPO) mediated cell death pathway, ferroptosis offers promises for anti‐tumor treatment. Photodynamic therapy (PDT) is an ideal way to generate reactive oxygen species (ROS) for LPO. However, the conventional PDT normally functions on subcellular organelles, such as endoplasmic reticulum, mitochondria, and lysosome, causing rapid cell death before triggering...
The combination of photodynamic therapy (PDT) and chemotherapy (chemo‐photodynamic therapy) for enhancing cancer therapeutic efficiency has attracted tremendous attention in the recent years. However, limitations, such as low local concentration, non‐suitable treatment light source, and uncontrollable release of therapeutic agents, result in reduced combined treatment efficacy. This study considered...
Carrier‐Free ATP‐Activated Nanoparticles
In article number 2205825, Wen Sun and co‐workers develop ingenious adenosine triphosphate (ATP)‐activated nanoparticles (CDNPs) that are directly self‐assembled from photosensitizer (Cy‐I) and amphiphilic Cd(II) complex (DPA‐Cd). In cancer cells, CDNPs are disintegrated by ATP to release Cy‐I for generating single oxygen under 808 nm light and DPA‐Cd concurrently...
As a non‐invasive treatment modality, photodynamic therapy has been a potential therapeutic method for metastatic and non‐metastatic tumors. In order to further improve the tumor selectivity, phtotoimmunotherapy (PIT) has been developed recently, which includes antibodies as the active targeting ligands. However, traditional monoclonal antibody‐based PIT suffers from long half‐lives and extended phototoxic...